drugset / Trial / NCT05577000
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
Phase 1
Active not recruiting
5 enrolled
Thomas Martin, MD
Actavis Inc. · collabEugia Pharma Specialities Limited · collabUniversity of California, Davis · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
Timeline
- Start
- 2021-10-18
- Primary completion
- 2025-11-30
- Completion
- 2038-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-BCMA CAR T cells | Cell therapy | 1.5e+08 cells | Intravenous |
| Subject | Anti-BCMA CAR T cells | Cell therapy | 4.5e+08 cells | Intravenous |
| Subject | Anti-BCMA CAR T cells | Cell therapy | 6e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |